The PALOMA-3 study found that palbociclib significantly extended progression-free survival for women with hormone-receptor-positive metastatic breast cancer, reducing cancer recurrence by 25% compared to chemotherapy alone. The treatment was well-tolerated and improved quality of life, offering a new hope for women with advanced disease.
A Yale University study found that removing more tissue during a partial mastectomy can spare thousands of breast cancer patients from a second surgery. The study showed that cavity shave margins reduced positive margin rates in half without compromising cosmetic outcomes or increasing complication rates.
The SIRFLOX randomized controlled study found that adding liver-directed SIR-Spheres Y-90 resin microspheres to first-line chemotherapy improved liver tumour control and reduced progression risk. The regimen provided a 7.9-month treatment benefit, translating to a 31% reduction in tumour progression risk.
A new study finds that anastrozole significantly reduces breast cancer recurrence in postmenopausal women with non-invasive DCIS, outperforming tamoxifen. The treatment also improves disease-free survival and overall survival rates for patients.
A recent Mayo Clinic study found that combining the targeted drug ibrutinib with standard chemotherapy significantly reduces the risk of death or cancer progression in patients with relapsed CLL or SLL. The treatment results in a nearly 80% reduction in mortality, offering new hope for longer disease control and decreased risk of relapse.
A study has identified a possible new combination chemotherapy regimen for patients with advanced metastatic castrate-resistant prostate cancer. The treatment, combining cabazitaxel and carboplatin, significantly extended progression-free survival by 2.3 months compared to single-agent therapy.
Pacritinib significantly reduced severe spleen enlargement and debilitating side effects in over 20% and 46% of patients, respectively. The therapy also showed promise in treating thrombocytopenia, a life-threatening condition often associated with myelofibrosis.
The ESMO Magnitude of Clinical Benefit Scale (ESMO-MCBS) provides a rational approach to grading the magnitude of clinical benefit of anti-cancer medicines. The scale will be applied to new drugs approved by the EMA, with high-scoring drugs highlighted in the ESMO Clinical Practice Guidelines.